Condition category
Circulatory System
Date applied
05/09/2014
Date assigned
05/09/2014
Last edited
17/10/2014
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
In this study we aim to test whether a mobile health home monitoring system, which is linked to patients’ health records and able to provide specialist alert and advice to patients and predictive clinical decision support tools to healthcare practitioners, can improve heart failure patients’ management.

Who can participate?
Adult men and women diagnosed with heart failure.

What does the study involve?
Participants are randomly allocated to either receive personalised feedback on their health or not. Participants are given and taught how to use a tablet PC to answer a short series of questions about their health and wellbeing and record their blood pressure, weight and heart rate. They are asked to complete these questions and measurements on a daily or regular basis for a period of about 6 months. Some participants may also be asked to carry a small monitor (FitBit) to record information about their level of physical activity and sleeping pattern. All of this data is captured and stored securely on the tablet PC and then wirelessly transferred in real-time to secure central servers at the University of Oxford where it is reviewed by researchers. Depending on treatment allocation and participant’s health monitoring data, they may receive more or less intensive feedback to support themselves in managing their condition better at home.

What are the possible benefits and risks of participating?
We hope that everyone taking part will improve their knowledge and understanding of managing heart failure. In addition, we hope that the intervention will improve partcipants' medication management and quality of life. However, we cannot guarantee this. The information we gain from this study may help us to treat patients with heart failure better in the future. There are no expected harms from participating into this study.

Where is the study run from?
The study is run from the participants’ homes.

When is the study starting and how long is it expected to run for?
The study starts in September 2014 and will run for a year.

Who is funding the study?
National Institute for Health Research (NIHR) (UK).

Who is the main contact?
Dr Kazem Rahimi
kazem.rahimi@cardiov.ox.ac.uk

Trial website

Contact information

Type

Scientific

Primary contact

Dr Kazem Rahimi

ORCID ID

Contact details

Old Road
Headington
Oxford
OX3 7LF
United Kingdom
kazem.rahimi@cardiov.ox.ac.uk

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

17276

Study information

Scientific title

Home monitoring with integrated risk-stratified disease management support versus home monitoring alone in patients with heart failure: a randomised controlled trial

Acronym

SUPPORT-HF 2 study, v1.0

Study hypothesis

In patients with heart failure, home monitoring coupled with an integrated data analysis and risk prediction service, providing real-time alerts and advice to patients and predictive clinical decision support tools to healthcare practitioners, is more effective in optimising medical therapy than home monitoring with the same monitoring equipment but without the use of the integrated data analysis and decision support service and the tailored self-management tools.

Ethics approval

14/SS/1025; First MREC approval date 28/08/2014

Study design

Randomised; Interventional; Design type: Prevention

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Other

Trial type

Prevention

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Topic: Cardiovascular disease; Subtopic: Cardiovascular (all Subtopics); Disease: Heart Failure

Intervention

Intervention: Collection of symptoms, physiological and system usage information from commercially available home monitoring devices and their integration with electronic health records (EHRs) for estimation of fluid status and risk. Risk-based algorithmic management supported by a specialist medical team and computer algorithms.

Control: Collection of symptoms, physiological and system usage information from commercially available home monitoring devices, as well as biochemical data from EHRs, but the data collected will not processed to provide personalised feedback to patients for self-management or to their doctors for risk-based monitoring or drug management. Participants’ pharmacological care will not be supported by the system.

Intervention type

Other

Phase

Not Applicable

Drug names

Primary outcome measures

Optimal medical therapy: Optimal medical therapy is defined as treatment consistent with the NICE guidelines for management of patients with chronic heart failure and will be measured as a composite opportunity score.

Secondary outcome measures

Not provided at time of registration

Overall trial start date

01/09/2014

Overall trial end date

01/09/2015

Reason abandoned

Eligibility

Participant inclusion criteria

1. Participant is willing and able to give informed consent for participation in the trial
2. Male or female, aged 18 years or above
3. Diagnosed with heart failure, defined as presence of typical symptoms (e.g. breathlessness, ankle swelling, and fatigue) and signs (e.g. elevated jugular venous pressure, pulmonary crackles, and displaced apex beat) resulting from an abnormality of cardiac structure or function
4. Potential to benefit from home monitoring and management defined as:
4.1. Self-assessed NYHA class II to IV; or
4.2. BNP >100 pg/L or NT-pro-BNP >360 pg/L in the last 30 days (excluding in-hospital measures)
AND either
4.3. Not on optimal therapy (in view of the Investigator), or
4.4. Probability of death within one year >10% (MAGGIC integer score 20 or more)
4.5. At least one hospital admission related to heart failure in the previous 12 months

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

Planned Sample Size: 250; UK Sample Size: 250

Participant exclusion criteria

1. No reliable 3G mobile or Wi-Fi network connectivity at home
2. Unable to read or speak English
3. Any other significant disease, including critical unstable or end-stage heart failure, which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial

Recruitment start date

01/09/2014

Recruitment end date

01/09/2015

Locations

Countries of recruitment

United Kingdom

Trial participating centre

Old Road , Headington
Oxford
OX3 7LF
United Kingdom

Sponsor information

Organisation

University of Oxford (UK)

Sponsor details

Wellcome Trust Centre for Human Genetics
Oxford
OX1 2JD
United Kingdom

Sponsor type

University/education

Website

Funders

Funder type

Government

Funder name

NIHR Career Development Fellowship (UK); Grant Codes: CDF-2013-06-012

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes